Edwards A Penny Shy, Beats Sales
Edwards Lifesciences Corporation (NYSE:EW) has reported an adjusted EPS of 38 cents in the third quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, and missing the year-ago quarter’s adjusted EPS of 43 cents. Revenues increased 18.3% to $412.7 million, exceeding the Zacks Consensus Estimate of $405 million. Segments Heart Valve Therapy remained [...]
Edwards Lifesciences Corporation (NYSE:EW) has reported an adjusted EPS of 38 cents in the third quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, and missing the year-ago quarter’s adjusted EPS of 43 cents. Revenues increased 18.3% to $412.7 million, exceeding the Zacks Consensus Estimate of $405 million.
Segments
Heart Valve Therapy remained the strongest segment at Edwards with an annualized growth of 22.7% to reach $246.1 million. Sales of surgical heart valves grew 7.7% to … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards